PARTNERSHIPS FOR DEVELOPMENT OF VACCINES TO PREVENT MYCOBACTERIUM TUBERCULOSIS INFECTION AND/OR DISEASE (R01 CLINICAL TRIAL NOT ALLOWED)

PARTNERSHIPS FOR DEVELOPMENT OF VACCINES TO PREVENT MYCOBACTERIUM TUBERCULOSIS INFECTION AND/OR DISEASE (R01 CLINICAL TRIAL NOT ALLOWED)

$750,000 direct costs per year and should reflect the actual needs of the project. - Friday, November 07, 2025

National Institute of Allergy and Infectious Disease
The purpose of this NOFO is to solicit research applications focused on preclinical development of lead candidate vaccines to prevent Mycobacterium tuberculosis infection and/or disease, and to increase the clinical pipeline of viable vaccine candidates.

Funding Opportunity

Visit the funding page (members only, sign in): PARTNERSHIPS FOR DEVELOPMENT OF VACCINES TO PREVENT MYCOBACTERIUM TUBERCULOSIS INFECTION AND/OR DISEASE (R01 CLINICAL TRIAL NOT ALLOWED)

Sign in or register for free to read the full details and apply

Sign in Create a free account

Share:

All funding opportunities